IVAX Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic reagent, instrumentation and software firm announces Sept. 2 that a group of purchasers controlled by industry entrepreneurs Paul Kennedy and Patrice Debregeas have purchased the approximately 72% of Ivax shares owned by Teva Pharmaceutical Industries for $14 million, or $0.70 per share. Kennedy and Debregeas will join Ivax's board of directors and Kennedy is expected to lead the firm's executive management team. Kennedy and Debregeas plan to expand the menu of test kits that Ivax offers in the U.S. and Italy to include other infectious diseases and autoimmune testing sectors
You may also be interested in...
Business News In Brief
EndoGastric Solutions raises $30 million: Maker of endoluminal devices for treating gastrointestinal disease raises $30 million in a "Series F" private placement led by Canaan Partners and Radius Ventures, announced Aug. 30. The proceeds will "support the company through profitability" and fund clinical trials and commercialization efforts for the firm's natural orifice surgery offerings, the company says. Privately held EndoGastric Solutions currently offers its 510(k)-cleared EsophyX and StomaphyX transoral systems for upper gastrointestinal procedures. Ongoing randomized clinical trials are further evaluating EsophyX for transoral incisionless fundoplication to treat gastroesophageal reflux disease and StomaphyX to reduce weight regained after gastric bypass procedures. "Our goal is to establish [natural orifice surgery] as the standard of care for patients with chronic acid reflux whose clinical needs are not met with medical management, and in the future, patients who suffer from obesity," stated CEO Thierry Thaure
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.